Join
Live feed
·
PRReleasevia Quantisnow
Maze Therapeutics Inc. logo

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

ByQuantisnow·Wall Street's wire, on your screen.
MAZE· Maze Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MAZE (Maze Therapeutics Inc.) and more on Quantisnow.